DBV Technologies, the Geneva University Hospitals and BioNet-Asia presented new data from a Phase I study evaluating the safety and immunogenicity of boosting young adults against pertussis toxin with an investigational epicutaneous patch containing recombinant PT. The new results, which were presented at the European Congress of Immunology in by Dr. Olga Chatzis and Prof. Claire-Anne Siegrist, highlighted data from two additional cohorts showing that following skin preparation with an epidermal laser, anti-PT booster responses elicited by Viaskin-PT were comparable to those elicited by Boostrix dTpa, an injectable approved booster vaccine, DBV said in a statement. In March 2017, data from this study reported no detectable immunogenicity signal following the application of Viaskin-PT on intact skin, it added. Data presented showed favorable safety and immunogenicity responses in healthy adults who received two applications of Viaskin-PT following skin preparation with an epidermal laser, DBV said. No serious adverse events were reported. The company “continues to evaluate these positive
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.